No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
ACC.24
Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
- Martin Maron, MD
Long-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
Long-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
ACC.24
Long-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
- Alexander Fanaroff, MD
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
ACC.24
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
- Akshay S. Desai, MD
Promising results for self-expanding TAVR device in trial with mostly women
Promising results for self-expanding TAVR device in trial with mostly women
ACC.24
Promising results for self-expanding TAVR device in trial with mostly women
- Hadley Wilson, MD